GAZYVA (obinutuzumab) Patient Assistance Program
Don’t let the high cost of brand specialty leukemia/lymphoma therapy stand between you and the treatment you need. We help eligible patients access Gazyva (obinutuzumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Gazyva (obinutuzumab) is FDA-approved in combination with chlorambucil for previously untreated chronic lymphocytic leukemia (CLL), in combination with bendamustine followed by single-agent maintenance for relapsed or refractory follicular lymphoma after a rituximab regimen, and in combination with chemotherapy followed by single-agent maintenance for previously untreated follicular lymphoma.
- Without assistance, Gazyva costs commonly run $7,000–$10,000+ per IV infusion. A complete CLL course (6 cycles) commonly totals $50,000–$70,000; follicular lymphoma maintenance can total $100,000+ over 2 years.
- Through AffordMyPrescriptions, qualifying patients can access Gazyva coverage for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- There is no biosimilar version of Gazyva available in the U.S. as of 2026.
What Is Gazyva Prescription Assistance Program?
The Gazyva Prescription Assistance Program is a manufacturer-sponsored initiative that provides Gazyva infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for CLL and lymphoma patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, HBV screening documentation (required to prevent hepatitis B reactivation), infusion scheduling, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Gazyva infusions cost roughly $7,000–$10,000+ each. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (typical) | ~$8,500.00 | Save ~$8,430/dose |
| First cycle (split dose) | ~$8,500/cycle | Save ~$8,430/cycle |
| CLL course (6 cycles) | ~$60,000+ | Save ~$59,000+ total |
| FL induction + maintenance | ~$100,000+ | Save ~$99,000+ total |
| Annual maintenance (FL) | ~$50,000+ | Save ~$49,000+/yr |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Gazyva Prescription Program?
The Patient Assistance Program is free to apply for and provides Gazyva infusions at little or no medication cost if approved. But the process involves detailed applications, oncology-team coordination, HBV screening documentation, infusion scheduling (with split first-cycle dosing), and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Gazyva:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $7,000–$10,000+ per infusion per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Gazyva assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Gazyva Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Gazyva:
Gazyva (obinutuzumab) is an intravenous (IV) anti-CD20 monoclonal antibody used to treat chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is a glycoengineered antibody that binds CD20 differently than rituximab and produces stronger antibody-dependent cellular cytotoxicity. Gazyva is given in combination with chemotherapy for induction, often followed by single-agent maintenance.
How Gazyva Works:
Gazyva targets B-cell cancers like CLL and follicular lymphoma by binding to the CD20 marker on malignant cells. As a glycoengineered Type II antibody, it is designed to trigger a stronger immune response and more direct cell killing than older treatments. This enhanced mechanism allows the immune system to more effectively destroy cancerous B-lymphocytes, leading to improved outcomes in specific clinical settings.
Form and use:
This medication is administered as an intravenous (IV) infusion, with the initial dose typically split over two days to manage the risk of reactions. Following the first cycle, it is usually given on a specific schedule of Days 8 and 15, then moving to once per cycle for subsequent treatments. Patients are given premedications like corticosteroids and antihistamines to ensure the infusion process is as safe and comfortable as possible.
Generic availability:
As of 2026, there is no biosimilar version of Gazyva available in the United States. While other anti-CD20 antibodies like rituximab have lower-cost biosimilars on the market, Gazyva remains a distinct brand-name therapy. The determination of whether Gazyva or an alternative like Arzerra is appropriate depends on the specific cancer type, treatment history, and clinical factors.
Warnings:
Gazyva carries serious boxed warnings for Hepatitis B reactivation and a rare brain infection known as PML, requiring screening before starting treatment. Other significant concerns include severe infusion reactions, particularly during the first dose, and the potential for tumor lysis syndrome or low white blood cell counts. Additionally, patients should avoid live vaccines while undergoing therapy to prevent complications.
FAQ (Frequently Asked Questions)
How Much Does Gazyva Cost Without Insurance?
Per-infusion costs commonly run $7,000–$10,000+. A complete CLL course (6 cycles) commonly totals $50,000–$70,000; follicular lymphoma induction + 2-year maintenance can total $100,000+. Through AffordMyPrescriptions, qualifying patients receive Gazyva at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Gazyva Different From Rituxan (Rituximab)?
Both are anti-CD20 antibodies, but Gazyva is a Type II glycoengineered antibody that binds a different CD20 epitope and produces stronger antibody-dependent cellular cytotoxicity. Clinical trials have shown improved efficacy compared to rituximab in some settings (especially first-line CLL). The trade-off is more frequent infusion reactions, particularly with the first dose.
Why Is The First Cycle Split Over Two Days?
The first infusion of Gazyva is split over Day 1 (100 mg) and Day 2 (900 mg) to reduce the risk of severe infusion reactions, which are most common with the first dose. After the split first cycle, subsequent infusions are given as a single dose. Premedication with corticosteroids, acetaminophen, and an antihistamine is also given to reduce infusion-reaction risk.
Why Is HBV Screening Required Before Starting Gazyva?
All anti-CD20 antibodies (Gazyva, Rituxan, etc.) carry a risk of reactivating chronic or resolved hepatitis B virus (HBV) infection — which can lead to fulminant hepatitis. Before starting Gazyva, you’ll be screened for HBV (HBsAg and anti-HBc), and if you have evidence of prior infection, you’ll typically be co-treated with an antiviral throughout therapy and for several months after.
Can I Get Gazyva Through The PAP If I Have Medicare?
Yes. Medicare beneficiaries can typically qualify for Gazyva Patient Assistance, especially if you face significant out-of-pocket costs under medical or pharmacy benefits. The manufacturer’s commercial copay assistance program is reserved for commercially insured patients only.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation, HealthWell Foundation, or the Leukemia & Lymphoma Society Co-Pay Assistance Program, or asking your oncology team whether rituximab (or its biosimilars at significantly lower cost) would be a clinical fit. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Gazyva, our team may be able to help you access assistance programs designed to make brand specialty leukemia/lymphoma therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.